Selective bromodomain inhibition of fungal bdf1

A compound of Formula II or III:

• wherein:
• X is NH, NHC(O), O or S;
• Ring A and Ring B are each independently a substituted or non-substituted aryl or a substituted or non-substituted heteroaryl;
• R1, R2, R3 and R4 are each independently H, Alk, OH, NH2, NHAlk, OAlk, halo, cycloalkyl, C(O)OH, C(O)OAlk, C(O)NH2, C(O)NHAlk, S(O)2OH, S(O)2NH2, S(O)2NHAlk, or NHC(O)Alk, wherein Alk is a substituted or non-substituted C1-C18 alkyl or ((CH2)nO)xCH3 where n is 2-4 and x is 1-4;
• R5 is H, Alk, OH, NH2, NHAlk, OAlk, halo, cycloalkyl, C(O)OH, C(O)OAlk, C(O)NH2, C(O)NHAlk, S(O)2OH, S(O)2NH2, S(O)2NHAlk, or NHC(O)Alk, wherein Alk is substituted or non-substituted C1-C18 alkyl or ((CH2)nO)xCH3 where n is 2-4 and x is 1-4, or R10 where R10 is piperidin-1-yl, morpholino or another nitrogen-containing heterocyclic substituent;
• and
• R6 is H, Alk, OH, NH2, NHAlk, OAlk, halo, cycloalkyl, C(O)OH, C(O)OAlk, C(O)NH2, C(O)NHAlk, S(O)2OH, S(O)2NH2, S(O)2NHAlk, or NHC(O)Alk, wherein Alk is substituted or non-substituted C1-C18 alkyl or ((CH2)nO)xCH3 where n is 2-4 and x is 1-4;
• or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

A compound of Formula IV:

• wherein:
• X is CH2, O, NH, or S;
• R is —(CH2)n-L, wherein n is 0-4 and L is H, halo, R1, —COO—R1, —CO—R1, —CO—N(R1R2), —S(O)2—R1, —S(O)2—N(R1R2), —N(R1R2), —N(R2)COR1, a substituted or non-substituted aryl, or a substituted or non-substituted heteroaryl,
• wherein R1 and R2 are each independently:
• (i) H, halo, a substituted or non-substituted aryl or a substituted or non-substituted heteroaryl;
• (ii) a substituted or non-substituted heterocycloalkyl;
• or
• (iii) a C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl, each comprising 0, 1, 2, or 3 heteroatoms selected from the group consisting of O, S, and N;
• or a substituted or non-substituted C3-C12 cycloalkyl or substituted or non-substituted C3-C12 cycloalkenyl;
• and
• R3 is (i) H, halo, a substituted or non-substituted aryl, or a substituted or non-substituted heteroaryl;
• (ii) a substituted or non-substituted heterocycloalkyl;
• (iii) a C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl, each comprising 0, 1, 2, or 3 heteroatoms selected from the group consisting of O, S, and N;
• or a substituted or non-substituted C3-C12 cycloalkyl or substituted or non-substituted C3-C12 cycloalkenyl;
• or (iv) OH, or a substituted or non-substituted amine, ether, amide, or ester;
• Z is a linking moiety wherein the linking moiety is a divalent radical of 1 to 40 atoms in a linear chain, wherein the linear chain comprises at least one carbon or nitrogen atom, and when the linear chain comprises 2 to 40 atoms, the chain comprises 0-8 heteroatoms selected from the group consisting of O, S, and N, which chain is optionally interrupted by 1 or 2 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups;
• Ring A is a substituted or non-substituted aryl or a substituted or non-substituted heteroaryl;
• R11 and R12 are each independently H, Alk, OH, NH2, NHAlk, OAlk, halogen, cycloalkyl, C(O)OH, C(O)OAlk, C(O)NH2, C(O)NHAlk, S(O)2OH, S(O)2NH2, or S(O)2NHAlk, wherein Alk is a substituted or non-substituted C1-C4 alkyl;
• R15 is H, Alk, OH, NH2, NHAlk, OAlk, halo, cycloalkyl, C(O)OH, C(O)OAlk, C(O)NH2, C(O)NHAlk, S(O)2OH, S(O)2NH2, or S(O)2NHAlk, wherein Alk is a substituted or non-substituted C1-C4 alkyl or RZ, where RZ is piperidin-1-yl, morpholino or another nitrogen-containing heterocyclic substituent;
• and
• R16 is H, Alk, OH, NH2, NHAlk, OAlk, halo, cycloalkyl, C(O)OH, C(O)OAlk, C(O)NH2, C(O)NHAlk, S(O)2OH, S(O)2NH2, or S(O)2NHAlk, wherein Alk is a substituted or non-substituted C1-C4 alkyl;
• or a pharmaceutically acceptable salt, solvate, or prodrug thereof.